Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157.
Sikiric. Predrag P; Seiwerth. Sven S; Rucman. Rudolf R; Turkovic. Branko B; Rokotov. Dinko Stancic DS; Brcic. Luka L; Sever. Marko M; Klicek. Robert R; Radic. Bozo B; Drmic. Domagoj D; Ilic. Spomenko S; Kolenc. Danijela D; Aralica. Gorana G; Safic. Hana H; Suran. Jelena J; Rak. Davor D; Dzidic. Senka S; Vrcic. Hrvoje H; Sebecic. Bozidar B
Key Findings
- BPC‑157 has a strong safety record with no reported toxicity even at high doses.
- In animal studies it reduced damage caused by NSAIDs in the gastrointestinal tract, liver, brain, and blood vessels.
- It improved wound healing, reduced bleeding and thrombocytopenia, and helped with pain and inflammation.
Practical Outcomes
- For biohackers, BPC‑157 looks promising as a protective supplement when using NSAIDs, potentially lowering gut irritation and bleeding risk. However, most data come from pre‑clinical work, so exact dosing protocols for humans are not established yet. If you choose to try it, start with the low microgram‑range doses used in studies and monitor any side‑effects.
Summary
The abstract says that the peptide BPC‑157 is very safe and helps heal ulcers, wounds, and many organ injuries. The authors think it could also act like an antidote to the harmful side‑effects of NSAIDs (like aspirin), protecting the stomach, liver, brain and even helping with bleeding problems. All the benefits were seen at very low doses given by mouth or injection.
Abstract
Stable gastric pentadecapeptide BPC 157 is an anti-ulcer peptidergic agent, proven in clinical trials to be both safe in inflammatory bowel disease (PL-10, PLD-116, PL 14736) and wound healing, stable in human gastric juice, with no toxicity being reported. Recently, we claim that BPC 157 may be used as an antidote against NSAIDs. We focused on BPC 157 beneficial effects on stomach, duodenum, intestine, liver and brain injuries, adjuvant arthritis, pain, hyper/hypothermia, obstructive thrombus formation and thrombolysis, blood vessel function, counteraction of prolonged bleeding and thrombocytopenia after application of various anticoagulants and antiplatelet agents and wound healing improvement. The arguments for BPC 157 antidote activity (i.e., the role of BPC 157 in cytoprotection, being a novel mediator of Robert's cytoprotection and BPC 157 beneficial effects on NSAIDs mediated lesions in the gastrointestinal tract, liver and brain and finally, counteraction of aspirin-induced prolonged bleeding and thrombocytopenia) obviously have a counteracting effect on several established side-effects of NSAIDs use. The mentioned variety of the beneficial effects portrayed by BPC 157 may well be a foundation for establishing BPC 157 as a NSAIDs antidote since no other single agent has portrayed a similar array of effects. Unlike NSAIDs, a very high safety (no reported toxicity (LD1 could be not achieved)) profile is reported for BPC 157. Also, unlike the different dosage levels of aspirin, as a NSAIDs prototype, which differ by a factor of about ten, all these beneficial and counteracting effects of BPC 157 were obtained using the equipotent dosage (μg, ng/kg) in parenteral or peroral regimens.
Study Information
pubmed
2013
2012-12-31T00:00:00.000Z
10.2174/13816128130111
30
105